Table 2.

Relationship of lupus antibodies to thrombocytopenia in 387 patients with familial lupus

ThrombocytopenicNonthrombocytopenic
EAAAHATotalEAAAHATotal
Anti-dsDNA         
 Positive 17* 12† 2 31‡ 79 54 6 139 
 Negative 10 3 3 16 127 64 10 201 
Anti-Ro/SSA         
 Positive 6 92-153 2 14 36 24 1 64 
 Negative 21 6 3 33 170 94 15 176 
Antiphospholipid         
 Positive 152-155 62-154 3 24# 52 19 5 76 
 Negative 12 9 2 23 154 99 11 264 
ThrombocytopenicNonthrombocytopenic
EAAAHATotalEAAAHATotal
Anti-dsDNA         
 Positive 17* 12† 2 31‡ 79 54 6 139 
 Negative 10 3 3 16 127 64 10 201 
Anti-Ro/SSA         
 Positive 6 92-153 2 14 36 24 1 64 
 Negative 21 6 3 33 170 94 15 176 
Antiphospholipid         
 Positive 152-155 62-154 3 24# 52 19 5 76 
 Negative 12 9 2 23 154 99 11 264 
*

χ2 = 6.0, P = .02, odds ratio = 2.73 (95% CI, 1.2-6.1) compared with European American patients with nonthrombocytopenic SLE.

†

χ2 = 6.2, P = .01, odds ratio = 4.7 (95% CI, 1.4-16.2) compared with African American patients with nonthrombocytopenic SLE.

‡

χ2 = 10.5, P = .001, odds ratio = 2.8 (95% CI, 1.5-5.2) compared with nonthrombocytopenic SLE patients.

F2-153

χ2 = 11.2, P < .001, odds ratio = 5.9 (95% CI, 2.1-16.6) compared with African American patients with nonthrombocytopenic SLE.

F2-155

χ2 = 10.7, P = .001, odds ratio = 3.7 (95% CI, 1.7-8.1) compared with European American patients with nonthrombocytopenic SLE.

F2-154

χ2 = 5.0, P = .03, odds ratio = 3.5 (95% CI, 1.1-10.9) compared with African American patients with nonthrombocytopenic SLE.

#χ2 = 17.8, P < .0001, odds ratio = 3.6 (95% CI, 2.0-6.6) compared with patients with nonthrombocytopenic SLE.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal